| Literature DB >> 30590210 |
Sheikh F Ahmad1, Mushtaq A Ansari2, Ahmed Nadeem2, Saleh A Bakheet2, Laila Y Al-Ayadhi3, Moureq R Alotaibi2, Ali R Alhoshani2, Musaad A Alshammari2, Sabry M Attia4.
Abstract
Evidence suggests that immune dysregulation is associated with autism spectrum disorder (ASD). T cell immunoglobulin and mucin domain-3 (TIM-3) has a critical role in several inflammatory disorders; however, the role of TIM-3 signaling has not been demonstrated in ASD. In the present study, we assessed the role of TIM-3 signaling in children with ASD. We expected that increased numbers of TIM-3+ cells could alter immune function in children with ASD. We revealed production of TIM-3 on CD3+, CD4+, CD8+, CD11a+,b+, CD14+, CD62P+, and CXCR5+ PBMCs in children with ASD and typically developing (TD) controls using immunofluorescent staining. We further demonstrated the production of IL-1β, IFN-γ, IL-17 A, and Foxp3 in TIM-3+ PBMCs of TD controls and individuals with ASD. We also observed the mRNA expression levels of TIM-3, CD11a,b, CD14, IL-1β and IFN-γ using RT-PCR. We further assessed the protein levels of TIM-3, IL-1β, CXCR5, and IFN-γ using western blotting. The results showed that children with ASD had increased numbers of CD3+TIM-3+, CD4+TIM-3+, CD8+TIM-3+, CD11a,b+TIM-3+, CD14+TIM-3+, CD62P+TIM-3+ and CXCR5+TIM-3+ cells compared with TD controls. Our results further showed that children with ASD had increased IL-1β+TIM-3+, IFN-γ+TIM-3+, and IL-17+TIM-3+, and decreased Foxp3+TIM-3+ production compared with that in TD controls. Our results indicated that children with ASD significantly induced TIM-3, CD11a,b, CD14, CXCR5, IL-1β and IFN-γ mRNA and protein expression levels compared with TD controls. The results suggested that detection of TIM-3 signaling could contribute to the early diagnoses of ASD.Entities:
Keywords: Autism spectrum disorder; Cell surface receptor; Cytokines; Peripheral blood mononuclear cells; T cell immunoglobulin and mucin domain-3; Typically developing controls
Mesh:
Substances:
Year: 2018 PMID: 30590210 DOI: 10.1016/j.molimm.2018.12.020
Source DB: PubMed Journal: Mol Immunol ISSN: 0161-5890 Impact factor: 4.407